摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-fluorophenyl)-2-(2-(isopropylamino)thiazolo[5,4-b]pyridin-5-yl)-3-oxopropane-nitrile | 924287-88-7

中文名称
——
中文别名
——
英文名称
3-(2-fluorophenyl)-2-(2-(isopropylamino)thiazolo[5,4-b]pyridin-5-yl)-3-oxopropane-nitrile
英文别名
3-(2-Fluorophenyl)-2-(2-(isopropylamino)thiazolo[5,4-b]pyridin-5-yl)-3-oxopropanenitrile;3-(2-fluorophenyl)-3-oxo-2-[2-(propan-2-ylamino)-[1,3]thiazolo[5,4-b]pyridin-5-yl]propanenitrile
3-(2-fluorophenyl)-2-(2-(isopropylamino)thiazolo[5,4-b]pyridin-5-yl)-3-oxopropane-nitrile化学式
CAS
924287-88-7
化学式
C18H15FN4OS
mdl
——
分子量
354.408
InChiKey
BENBWXZMOXKZAL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    107
  • 氢给体数:
    1
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
    申请人:Liu Chunjian
    公开号:US20070185175A1
    公开(公告)日:2007-08-09
    A compound of Formula (I) or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein A is independently selected from: further wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and W are as described herein. Also disclosed is a compound of Formula (II) or an enantiomer, diastereomer, or a pharmaceutically-acceptable salt thereof, wherein each of G, X and Y are independently CH or N, wherein at each occurrence at least one of G, X or Y is N and the other two of G, X or Y are CH; and B is independently selected from: further wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 and Z are as described herein. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) and Formula (II), and methods of treating conditions associated with the activity of p38 kinase.
    公式(I)的化合物或其对映体,非对映异构体或其药学上可接受的盐,其中A是独立选择的,包括:进一步,其中R1、R2、R3、R4、R5、R6、R7和W如此描述。还公开了公式(II)的化合物或其对映体,非对映异构体或其药学上可接受的盐,其中G、X和Y中的每一个都是独立选择的CH或N,在每次出现时,至少有一个G、X或Y是N,而G、X或Y的另外两个是CH;B是独立选择的,包括:进一步,其中R1、R2、R3、R4、R5、R8、R9和Z如此描述。还公开了包含公式(I)和公式(II)的化合物的药物组合物,以及治疗与p38激酶活性相关的疾病的方法。
  • BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS
    申请人:Liu Chunjian
    公开号:US20090118272A1
    公开(公告)日:2009-05-07
    A compound of Formula (I) an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein A is independently selected from: further wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and W are as described herein. Also disclosed is a compound of Formula (II) an enantiomer, diastereomer, or a pharmaceutically-acceptable salt thereof, wherein each of G, X and Y are independently CH or N, wherein at each occurrence at least one of G, X or Y is N and the other two of G, X or Y are CH; and B is independently selected from: further wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 and Z are as described herein. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) and Formula (II), and methods of treating conditions associated with the activity of p38 kinase.
    公式(I)的化合物,其对映异构体、顺反异构体或其药学上可接受的盐,其中A是独立选择的,包括:进一步,其中R1、R2、R3、R4、R5、R6、R7和W如此描述。还披露了公式(II)的化合物,其对映异构体、顺反异构体或其药学上可接受的盐,其中G、X和Y中的每个都是独立选择的CH或N,其中在每次出现时,至少有一个G、X或Y是N,而另外两个G、X或Y是CH;B是独立选择的,包括:进一步,其中R1、R2、R3、R4、R5、R8、R9和Z如此描述。还披露了包含公式(I)和公式(II)的化合物的制药组合物,以及治疗与p38激酶活性相关的疾病的方法。
  • Benzothiazole compounds useful as kinase inhibitors
    申请人:Bristol-Myers Squibb Company
    公开号:EP2266981A2
    公开(公告)日:2010-12-29
    A compound of Formula (I) or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein A is independently selected from: further wherein R1, R2, R3, R4, R5, R6, R7, and W are as described herein. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and the use of said compounds for treating conditions associated with the activity of p38 kinase.
    式 (I) 的化合物 或 其对映体、非对映体或药学上可接受的盐,其中 A 独立选自 进一步 其中 R1、R2、R3、R4、R5、R6、R7 和 W 如本文所述。 还公开了含有式(I)化合物的药物组合物,以及所述化合物用于治疗与 p38 激酶活性相关的病症的用途。
  • US7473784B2
    申请人:——
    公开号:US7473784B2
    公开(公告)日:2009-01-06
  • US7994337B2
    申请人:——
    公开号:US7994337B2
    公开(公告)日:2011-08-09
查看更多